Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $0.41-0.46 for the period, compared to the consensus EPS estimate of $0.43. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $388.90 million.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. UBS Group increased their target price on Certara from $17.00 to $20.00 and gave the company a neutral rating in a research note on Friday, March 1st. Jefferies Financial Group boosted their target price on shares of Certara from $14.00 to $15.50 and gave the company a hold rating in a research note on Friday, March 1st. JMP Securities initiated coverage on Certara in a research note on Thursday, April 4th. They set a market perform rating for the company. KeyCorp upgraded Certara from a sector weight rating to an overweight rating and set a $23.00 target price on the stock in a research note on Wednesday, April 10th. Finally, Barclays upped their price target on shares of Certara from $16.00 to $18.00 and gave the stock an equal weight rating in a research report on Thursday, January 25th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Certara presently has a consensus rating of Hold and an average target price of $20.06.

Certara Stock Up 0.1 %

Shares of Certara stock traded up $0.02 during midday trading on Tuesday, hitting $17.66. The company’s stock had a trading volume of 822,886 shares, compared to its average volume of 532,788. Certara has a 1-year low of $11.81 and a 1-year high of $23.54. The firm has a market capitalization of $2.83 billion, a P/E ratio of -50.46, a PEG ratio of 1.81 and a beta of 1.61. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $17.71 and a 200-day simple moving average of $16.42.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. The company had revenue of $88.01 million during the quarter, compared to analysts’ expectations of $86.80 million. As a group, sell-side analysts expect that Certara will post 0.29 earnings per share for the current year.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 14,427 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Certara news, insider Patrick F. Smith sold 14,427 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $844,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard M. Traynor sold 6,000 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $18.00, for a total transaction of $108,000.00. Following the transaction, the senior vice president now owns 165,368 shares in the company, valued at approximately $2,976,624. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,427 shares of company stock valued at $405,095. 2.39% of the stock is owned by insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.